Shares In Issue
As at 16 January 2019, the number of shares in issue was 71,395,148
As at 16 January 2019, shareholders holding more than 3% of the share capital of Venn Life Sciences Holdings plc were:
|Name||No. of ordinary shares||% of existing share capital|
|Livingbridge VC LLP||13,081,337||18.3%|
|Director||No. of ordinary shares||% of existing share capital|
Shares not in public hands
In the terms of AIM/ESM Rules published 13 May 2014 and insofar as it is aware, at 16 January 2019, 1.1% of the Company’s AIM/ESM securities was not in public hands.
Restrictions in transfer of AIM/ESM securities
There are no restrictions on the transfer of Venn Life Sciences Holdings plc’s AIM/ESM securities.
Other exchanges and trading platforms
Venn Life Sciences Holdings plc has admitted its AIM securities to trading on the Enterprise Securities Market.
|July 2018||Placing and Subscription|
|06 June 2018||Notice of AGM to be held on 27 June 2018 – Form of Proxy for AGM to be held on 27 June 2018|
|31 March 2017||Notice of AGM held on 26 April 2017 Form of Proxy for AGM held on 26 April 2017|
|10 October 2016||Venn-Innovenn-Circular-04-10-16|
|22 Sept 2016||Placing to raise £3,570,000, in connection with the proposed acquisition of Kinesis Pharma BV and Notice of General Meeting. Venn Life Sciences Circular & Venn Life Proxy.|
|13 March 2015||Placing to raise £2,000,000 and Notice of General Meeting held on 01 April 2015|
|14 March 2014||Notice of General Meeting held on 31 March 2014|
|13 June 2013||Notice of AGM held on 23 July 2013 – Proxy Form for AGM held on 23 July 2013|
UK City Code on Takeovers and Mergers
As an AIM traded UK registered company, Venn Life Sciences Holdings plc is subject to the UK City Code on Takeovers and Mergers legislation.